Joel White spoke with Inside Drug Pricing about the Biden Adminstration’s growing interest in value-based payments for prescription drugs.
CMS’ Center for Medicare and Medicaid Innovation (CMMI) is considering testing the use of value-based payments for prescription drugs among a list of potential demonstrations the government could test to lower drug costs, Joel White of Horizon Government Affairs says. The innovation center must develop a final report on demonstrations to cut drug costs by Jan. 12, as directed by an October presidential executive order.
White told Inside Drug Pricing that HGA has had conversations with CMMI officials and state Medicaid directors regarding the possibility of tying prices to the clinical value a drug is determined to have, and said the idea is something that the innovation center has been looking at and that Medicaid officials have a large interest in.
“I’d be surprised if it wasn’t in the report,” White said.